Ipca Laboratories Ltd
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
- Market Cap ₹ 36,735 Cr.
- Current Price ₹ 1,448
- High / Low ₹ 1,758 / 1,052
- Stock P/E 52.7
- Book Value ₹ 266
- Dividend Yield 0.28 %
- ROCE 14.2 %
- ROE 9.81 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 5.45 times its book value
- Promoter holding has decreased over last quarter: -1.58%
- The company has delivered a poor sales growth of 11.2% over past five years.
- Company has a low return on equity of 11.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Midcap 150 BSE 400 MidSmallCap Index Nifty MidSmallcap 400 Nifty Healthcare Index Nifty LargeMidcap 250
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,778 | 3,235 | 3,088 | 2,804 | 3,102 | 3,193 | 3,606 | 4,338 | 5,114 | 5,405 | 5,775 | 6,124 | 6,394 | |
2,216 | 2,498 | 2,556 | 2,526 | 2,666 | 2,748 | 2,909 | 3,419 | 3,596 | 4,164 | 4,858 | 4,909 | 5,074 | |
Operating Profit | 562 | 737 | 532 | 277 | 436 | 446 | 697 | 918 | 1,518 | 1,241 | 917 | 1,215 | 1,321 |
OPM % | 20% | 23% | 17% | 10% | 14% | 14% | 19% | 21% | 30% | 23% | 16% | 20% | 21% |
17 | 21 | 32 | 26 | 19 | 39 | 54 | 64 | 61 | 53 | 108 | -23 | -29 | |
Interest | 34 | 28 | 29 | 31 | 26 | 27 | 21 | 19 | 11 | 10 | 46 | 123 | 88 |
Depreciation | 84 | 101 | 177 | 161 | 171 | 174 | 172 | 179 | 188 | 210 | 229 | 246 | 249 |
Profit before tax | 461 | 629 | 358 | 111 | 258 | 283 | 557 | 785 | 1,380 | 1,074 | 750 | 822 | 955 |
Tax % | 28% | 24% | 28% | 17% | 27% | 18% | 18% | 17% | 17% | 20% | 33% | 35% | |
331 | 477 | 256 | 93 | 188 | 233 | 455 | 652 | 1,141 | 860 | 506 | 530 | 650 | |
EPS in Rs | 13.13 | 18.91 | 10.15 | 3.67 | 7.46 | 9.24 | 18.00 | 25.82 | 44.97 | 33.91 | 19.93 | 20.91 | 25.62 |
Dividend Payout % | 15% | 13% | 5% | 0% | 7% | 5% | 8% | 10% | 9% | 12% | 20% | 19% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 6% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | 6% |
3 Years: | -19% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 15% |
3 Years: | 13% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 11% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Reserves | 1,545 | 1,956 | 2,208 | 2,258 | 2,450 | 2,670 | 3,111 | 3,652 | 4,727 | 5,450 | 5,852 | 6,323 | 6,713 |
617 | 595 | 929 | 865 | 716 | 628 | 444 | 474 | 236 | 776 | 1,440 | 1,152 | 869 | |
522 | 641 | 662 | 756 | 777 | 785 | 877 | 1,033 | 1,021 | 1,186 | 1,129 | 1,159 | 1,300 | |
Total Liabilities | 2,709 | 3,217 | 3,824 | 3,905 | 3,968 | 4,108 | 4,458 | 5,185 | 6,010 | 7,438 | 8,447 | 8,659 | 8,908 |
1,075 | 1,306 | 1,753 | 1,977 | 1,946 | 1,855 | 1,740 | 1,841 | 1,869 | 2,153 | 2,479 | 2,524 | 2,539 | |
CWIP | 129 | 165 | 267 | 129 | 95 | 73 | 66 | 84 | 182 | 297 | 123 | 175 | 283 |
Investments | 22 | 29 | 82 | 97 | 212 | 216 | 322 | 649 | 868 | 1,339 | 1,057 | 2,654 | 2,721 |
1,482 | 1,717 | 1,722 | 1,702 | 1,716 | 1,964 | 2,329 | 2,611 | 3,092 | 3,650 | 4,789 | 3,306 | 3,365 | |
Total Assets | 2,709 | 3,217 | 3,824 | 3,905 | 3,968 | 4,108 | 4,458 | 5,185 | 6,010 | 7,438 | 8,447 | 8,659 | 8,908 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
387 | 515 | 455 | 696 | 271 | 324 | 496 | 561 | 1,096 | 832 | 762 | 831 | |
-261 | -362 | -686 | -214 | -146 | -119 | -123 | -499 | -560 | -812 | -710 | -1,355 | |
-81 | -138 | 255 | -414 | -156 | -130 | -223 | -139 | -307 | 426 | 506 | -465 | |
Net Cash Flow | 45 | 14 | 25 | 68 | -31 | 74 | 150 | -76 | 229 | 446 | 559 | -990 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 51 | 42 | 57 | 59 | 68 | 64 | 71 | 55 | 56 | 59 | 61 |
Inventory Days | 245 | 271 | 293 | 290 | 288 | 286 | 332 | 312 | 350 | 364 | 293 | 309 |
Days Payable | 89 | 109 | 97 | 145 | 128 | 136 | 146 | 133 | 121 | 101 | 80 | 78 |
Cash Conversion Cycle | 211 | 213 | 238 | 203 | 219 | 218 | 250 | 250 | 284 | 319 | 272 | 293 |
Working Capital Days | 113 | 98 | 107 | 86 | 95 | 109 | 113 | 117 | 123 | 130 | 123 | 123 |
ROCE % | 24% | 27% | 13% | 4% | 9% | 9% | 17% | 20% | 30% | 19% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16h - Conference call for Q3 FY25 earnings on February 13.
-
Order Received Under CGST Act
7 Feb - Received tax demand order under CGST Act.
-
Order Received Under Central Goods And Service Tax Act, 2017
5 Feb - Received tax demand order under CGST Act.
-
Orders Received Under CGST Act
29 Jan - Received tax demand orders under CGST Act.
-
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For Q3 And Nine Months Ended 31St December, 2024
27 Jan - Board meeting to consider Q3 financial results.
Annual reports
-
Financial Year 2023
from web
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Jun 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Apr 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]
Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]